Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 10 December 2025 - 12 December 2025

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Updated: December 12, 2025Company: Milestone Pharmaceuticals Inc. ( NASDAQ: MIST ) Milestone Pharmaceuticals Inc. stock is drawing heightened attention on December 12, 2025 , as investors position ahead of a make-or-break FDA decision for the company’s lead program, CARDAMYST™ (etripamil) nasal spray , aimed at treating paroxysmal supraventricular tachycardia (PSVT) . The regulatory catalyst arrives after a volatile year that…
12 December 2025
····
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock (NYSE: LLY) is back in the spotlight on December 12, 2025, as the market digests a rapid sequence of obesity-pipeline headlines—alongside new…
12 December 2025
···
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for its GLP‑1 franchise. As of Thursday’s close, Eli Lilly shares were trading around $1,006, up roughly 1–1.5% on the day,…
11 December 2025
····
Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Date: December 11, 2025 Centessa Pharmaceuticals plc (NASDAQ: CNTA) is back in the spotlight after a major leadership announcement and a sharp intraday pullback in its share price. On December 11, 2025, the company unveiled a CEO transition that will take effect at the start of 2026, just as its orexin program heads toward pivotal studies. GlobeNewswire Shares of Centessa…
11 December 2025
··
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term…
11 December 2025
····
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease. Immunovant, Inc. By late afternoon, Immunovant stock was trading around $25.75,…
11 December 2025
····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and a string of oncology milestones — capped by an HSBC upgrade that just put AbbVie on the firm’s “preferred buys”…
11 December 2025
····
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

On November 21, 2025, Eli Lilly and Company (NYSE: LLY) became the first pharmaceutical group ever to cross a $1 trillion market value, lifted by surging demand for its obesity and diabetes drugs Mounjaro and Zepbound. Reuters Since then, investors have been digesting that historic moment alongside a fresh wave of drug data, a multibillion‑dollar manufacturing build‑out in Alabama, and…
11 December 2025
····
Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (NYSE: PFE) heads into Thursday’s session with its share price hovering around yesterday’s close, as investors digest a flurry of news on cost cuts, obesity drug deals, and a big hedge fund trimming its stake. As of around 6:05 a.m. ET on Thursday, December 11, real‑time feeds put Pfizer stock near $25.78, roughly flat versus Wednesday’s close of $25.78…
11 December 2025
···
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly 6.5–7% with one of the cheapest valuations in big pharma, making it a focal point for income and value investors…
10 December 2025
···
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Published: December 10, 2025 Olema Pharmaceuticals Stock Rallies to Fresh Highs Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), which now brands itself as Olema Oncology, is having another breakout session on December 10, 2025. During Wednesday’s trading, OLMA: Over the past 12 months, OLMA’s share price has climbed from below $3 to nearly $30, according to Danelfin and CoinCodex ranges, reflecting a…
10 December 2025
··
Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck & Co., Inc. (NYSE: MRK) stock is treading water just below the $100 mark on Wednesday, December 10, 2025, as investors weigh a rich pipeline and fresh analyst upgrades against looming patent and pricing pressures. The day’s news flow is dominated by dividend chatter, options “whale” activity, new institutional ownership disclosures, and fresh signs that competition to flagship cancer…
10 December 2025
····
1 … 27 28 29 30 31 … 46

Stock Market Today

  • Palo Alto Networks (PANW) Valuation: Price Declines Amid High P/E Ratio Raise Questions
    January 22, 2026, 5:45 PM EST. Palo Alto Networks (PANW) shares have recently fallen, with declines over the past week, month, and three months, despite strong long-term returns of 139% over three years and 225% over five. The stock trades at $181.47 with a price-to-earnings (P/E) ratio of 113.2x, far exceeding the U.S. software industry average of 30.1x and peer average of 39x, indicating elevated market expectations for growth. A discounted cash flow (DCF) model suggests the stock may be undervalued at a 26.6% discount to intrinsic value ($247.24). Investors face a dilemma between high valuation multiples and DCF undervaluation amid recent price softness, highlighting cautious sentiment's impact on this cybersecurity leader.
Go toTop